Maliepaard M - Search Results

1

Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.

Crul M, Schoemaker NE, Pluim D, Maliepaard M, Underberg RW, Schot M, Sparidans RW, Baas P, Beijnen JH, Van Zandwijk N, Schellens JH. Crul M, et al. Among authors: maliepaard m. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3526-33. Clin Cancer Res. 2003. PMID: 14506138 Clinical Trial.

2

Interchangeability of generic drugs for subpopulations: Bioequivalence simulation from a nonparametric PK model of gabapentin generic drugs.

Glerum PJ, Yamada WM, Neely MN, Burger DM, Maliepaard M, Neef C. Glerum PJ, et al. Among authors: maliepaard m. Br J Clin Pharmacol. 2024 Jul;90(7):1576-1585. doi: 10.1111/bcp.15629. Epub 2023 Feb 2. Br J Clin Pharmacol. 2024. PMID: 36482842

3

Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1.

Ma J, Maliepaard M, Kolker HJ, Verweij J, Schellens JH. Ma J, et al. Among authors: maliepaard m. Cancer Chemother Pharmacol. 1998;41(3):186-92. doi: 10.1007/s002800050727. Cancer Chemother Pharmacol. 1998. PMID: 9443634

4

Cisplatin resistance and DNA repair.

Crul M, Schellens JH, Beijnen JH, Maliepaard M. Crul M, et al. Among authors: maliepaard m. Cancer Treat Rev. 1997 Sep-Nov;23(5-6):341-66. doi: 10.1016/s0305-7372(97)90032-3. Cancer Treat Rev. 1997. PMID: 9465884 Review. No abstract available.

5

Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.

Ma J, Maliepaard M, Nooter K, Boersma AW, Verweij J, Stoter G, Schellens JH. Ma J, et al. Among authors: maliepaard m. Cancer Chemother Pharmacol. 1998;41(4):307-16. doi: 10.1007/s002800050744. Cancer Chemother Pharmacol. 1998. PMID: 9488600

6

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.

Ma J, Maliepaard M, Nooter K, Loos WJ, Kolker HJ, Verweij J, Stoter G, Schellens JH. Ma J, et al. Among authors: maliepaard m. Br J Cancer. 1998 May;77(10):1645-52. doi: 10.1038/bjc.1998.270. Br J Cancer. 1998. PMID: 9635842 Free PMC article.

7

In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM.

de Graaff M, Maliepaard M, Pluim D, Floot BJ, Slaper-Cortenbach IC, Schellens JH. de Graaff M, et al. Among authors: maliepaard m. Anticancer Drugs. 1999 Feb;10(2):213-8. doi: 10.1097/00001813-199902000-00010. Anticancer Drugs. 1999. PMID: 10211552

8

Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.

Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH. Maliepaard M, et al. Cancer Res. 1999 Sep 15;59(18):4559-63. Cancer Res. 1999. PMID: 10493507

9

32P-postlabeling assay for the quantification of the major platinum-DNA adducts.

Pluim D, Maliepaard M, van Waardenburg RC, Beijnen JH, Schellens JH. Pluim D, et al. Among authors: maliepaard m. Anal Biochem. 1999 Nov 1;275(1):30-8. doi: 10.1006/abio.1999.4302. Anal Biochem. 1999. PMID: 10542106

10

Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.

Scheffer GL, Maliepaard M, Pijnenborg AC, van Gastelen MA, de Jong MC, Schroeijers AB, van der Kolk DM, Allen JD, Ross DD, van der Valk P, Dalton WS, Schellens JH, Scheper RJ. Scheffer GL, et al. Among authors: maliepaard m. Cancer Res. 2000 May 15;60(10):2589-93. Cancer Res. 2000. PMID: 10825126

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

69 results

Search Page

Filters